Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France

•Over a 5-year time-horizon, pembrolizumab improves LYs and QALYs vs. SoC chemotherapy.•The ICERs of pembrolizumab vs. SoC platinum-based chemotherapy were

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Lung cancer (Amsterdam, Netherlands) Netherlands), 2019-01, Vol.127, p.44-52
Hauptverfasser:	Chouaid, Christos, Bensimon, Lionel, Clay, Emilie, Millier, Aurélie, Levy-Bachelot, Laurie, Huang, Min, Levy, Pierre
Format:	Artikel
Sprache:	eng
Schlagworte:	Advanced NSCLC Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Combined Chemotherapy Protocols - therapeutic use B7-H1 Antigen - genetics Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - economics Carcinoma, Squamous Cell - drug therapy Carcinoma, Squamous Cell - economics Cost effectiveness Cost-Benefit Analysis Costs and Cost Analysis Delivery of Health Care Economics Female France Humans Lung Neoplasms - drug therapy Lung Neoplasms - economics Male Models, Econometric PD-L1 positive Pembrolizumab Platinum Compounds - therapeutic use Quality-Adjusted Life Years Quantitative Finance Standard of Care
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•Over a 5-year time-horizon, pembrolizumab improves LYs and QALYs vs. SoC chemotherapy.•The ICERs of pembrolizumab vs. SoC platinum-based chemotherapy were
ISSN:	0169-5002 1872-8332
DOI:	10.1016/j.lungcan.2018.11.008